NCT01681953View on ClinicalTrials.gov

A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Alpha-Mannosidosis
Interventions
DRUG

Lamazym

ERT, i.v. infusions weekly

DRUG

Placebo

Infusions weekly

Trial Locations (6)

55131

Universitätsmedizin Mainz, Zentrum für Kinder- und Jugendmedizin, Langenbeckstrasse 1, Mainz

69677

Hôpital Femme Mère Enfant, Lyon, 59 boulevard Pinel, Bron

DK-2100

Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen

75 571

Hôpital Trousseau, Service de neuropédiatrie, Centre Référence des Maladies Lysosomales, 26 avenue du Docteur Arnold Netter, Paris

04 730

The Children's Memorial Health Institute Warsaw, Department of Metabolic Diseases, Al Dzieci Polskich 20, Warsaw

M13 9WL

Genetic Medicine, 6th floor, St Mary's Hospital, Oxford Road,, Manchester

All Listed Sponsors
collaborator

European Commission

OTHER

lead

Zymenex A/S

INDUSTRY

NCT01681953 - A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis | Biotech Hunter | Biotech Hunter